G4

Qualigen Therapeutics CEO Michael Poirier Provides Letter to Shareholders

Retrieved on: 
Dienstag, Februar 22, 2022
GLOBE, Risk, Pancreatic cancer, Therapy, Partnership, Fastpacking, Mortality, Neoplasm, University College London Hospitals NHS Foundation Trust, Toxicity, Awareness, University, American Cancer Society, Letter, COVID-19, Pharmacotherapy, G4, American Association, Disease, Pancreas, LLC, Cancer, American Association for Cancer Research, Acquisition, AACR, University of Louisville School of Medicine, Adult, Acute myeloid leukemia, Recurrence, IND, News, Author, UCL, Nasdaq, University College London, Marketing, Patient, 2021 Essex County Council election, Survival, Rare Disease Day, Association, G4S, Pharmaceutical industry

As a result, we expect to see an increase in our revenue and per-unit profit margins from our flagship diagnostics business.

Key Points: 
  • As a result, we expect to see an increase in our revenue and per-unit profit margins from our flagship diagnostics business.
  • Qualigen will assume all commercial activities and distribution management for its diagnostics unit in the U.S. and international markets.
  • We were therefore thrilled to welcome Professor Neidle as a consultant to Qualigen as we prepare to initiate IND-enabling studies for QN-302.
  • We are off to a strong start for the year, with exciting new diagnostics opportunities and a clear path forward for our lead therapeutics program.

Qualigen Therapeutics Secures Worldwide Rights to G4-Selective Transcription Inhibitors from University College London to Develop as Cancer Therapeutics

Retrieved on: 
Dienstag, Januar 18, 2022
Cancer research, Survival, IP, Research, News, Treatment of lung cancer, University College London, Risk, Clinical trial, Private Securities Litigation Reform Act, Form 10-K, Prostate cancer, Cancer, Protein, Adult, Drug design, Disease, PDAC, AML, GLOBE, IND, Pancreatic cancer, Acute myeloid leukemia, U.S. Securities and Exchange Commission, History, Nasdaq, UCL School of Pharmacy, Therapy, Pharmacology, Program, Fatality, Company, Diagnosis, Orphan drug, G4S, RAS, Toxicity, UCL, Neoplasm, Patent, FDA, Security (finance), Lead, Pharmaceutical industry, G4, Pharmacy

CARLSBAD, Calif., Jan. 18, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a biotechnology company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, today announces the exclusive worldwide in-license of a genomic quadruplex (G4)-selective transcription inhibitor drug development program, including lead and back-up compounds, preclinical data and a patent estate, from University College London (UCL). Qualigen intends to develop the lead compound, now called QN-302, as a treatment for pancreatic ductal adenocarcinoma (PDAC), which represents the vast majority of pancreatic cancers. This license agreement was carried out by UCL Business Limited, the commercialization company for UCL.

Key Points: 
  • Qualigen intends to develop the lead compound, now called QN-302, as a treatment for pancreatic ductal adenocarcinoma (PDAC), which represents the vast majority of pancreatic cancers.
  • This program aligns with our oncology focused therapeutics pipeline, expands our IP portfolio, and positions Qualigen well in this exciting area of G4 cancer research, commented Michael Poirier, Qualigens Chief Executive Officer.
  • The scientific work UCL completed on the G4 platform could enable us to proceed with IND-enabling studies in 2022 toward an initial indication of pancreatic cancer.
  • This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

Singular Genomics Partners with Lexogen to Enable RNA Library Prep for the G4 Sequencing Platform

Retrieved on: 
Montag, Januar 10, 2022
Singular, RNA-Seq, Health, SEC, Efficiency, Biology, OMIC, Transcriptome, Federal, Science, Partnership, RNA, Genomics, Proteomics, Research, PX, Solution, Senior, NGS, Spatial analysis, Risk, Corporate development, Nasdaq, Technology, Medicine, GLOBE, Vaccine, G4

As pioneers in the field of RNA science, Lexogen has enabled RNA library preparation kits that are cost-efficient, streamlined and deliver complete transcript representation.

Key Points: 
  • As pioneers in the field of RNA science, Lexogen has enabled RNA library preparation kits that are cost-efficient, streamlined and deliver complete transcript representation.
  • We are pleased to partner with the RNA experts to make Lexogens kits available to Singular Genomics customers.
  • Lexogen is the leader in 3 RNA sequencing, a technology proven for its efficiency, its robustness, and its sensitivity.
  • Lexogens portfolio includes innovative kits for true single-cell as well as bulk RNA Sequencing, RNA purification and ribosomal RNA depletion, spike-in RNA variant controls, and metabolic RNA labeling.

Singular Genomics Partners with New England Biolabs® to Enable NEBNext® Kits for the G4 Sequencing Platform

Retrieved on: 
Montag, Januar 10, 2022
Singular, NEB, SEC, DNA, Molecular biology, Synthetic biology, OMIC, Industry, Gene expression, G4, Federal, Science, Partnership, RNA, Genomics, Proteomics, Solution, PCR, PX, Senior, NGS, Spatial analysis, Risk, Corporate development, Nasdaq, Medicine, GLOBE, NEW, Associate Director of National Intelligence and Chief Information Officer, Enzyme, Fine chemical, New England Biolabs

NEBNext kits are designed and quality controlled to improve yields and library diversity, using a broad range of input amounts from a wide variety of sample types.

Key Points: 
  • NEBNext kits are designed and quality controlled to improve yields and library diversity, using a broad range of input amounts from a wide variety of sample types.
  • We are pleased to partner with NEB to make the NEBNext kits available to Singular Genomics customers.
  • We are delighted to see an exciting new sequencing platform come to the NGS market, said Fiona Stewart, Ph.D., Associate Director, NGS Portfolio management.
  • The G4 and PX sequencing platforms are both comprised of an instrument and an associated menu of consumable kits.

Singular Genomics Partners with Watchmaker Genomics to Enable the Watchmaker DNA Library Prep Kits for the G4 Sequencing Platform

Retrieved on: 
Montag, Januar 10, 2022
Singular, SEC, DNA, Reading, Synthetic biology, OMIC, Marketing, G4, Protein engineering, Federal, Science, Partnership, RNA, Genomics, Research, PX, Solution, Proteomics, Watchmaker, NGS, Senior, Spatial analysis, Risk, Corporate development, Nasdaq, Medicine, GLOBE, Enzyme, Antibiotics, Fine chemical

We are pleased to leverage Watchmakers sequencing expertise to make their DNA library prep kits available to Singular Genomics customers.

Key Points: 
  • We are pleased to leverage Watchmakers sequencing expertise to make their DNA library prep kits available to Singular Genomics customers.
  • The rapid development and expansion of short-read sequencing platforms has proven to increase quality and choice for the genomics community, said Kerri Stellato, Vice President of Strategic Marketing at Watchmaker Genomics.
  • Watchmaker is excited to partner with Singular, and we look forward to continued collaboration to provide additional Watchmaker library prep chemistries for the G4 platform.
  • Watchmaker Genomics applies advanced enzymology to enable breakthrough applications for the reading, writing, and editing of DNA and RNA.

Singular Genomics Partners with Twist Bioscience to Enable the Twist NGS Target Enrichment Solutions for the G4 Sequencing Platform

Retrieved on: 
Montag, Januar 10, 2022
Singular, SEC, DNA, Drug discovery, Synthetic biology, Biology, OMIC, Engineering, Silicon, G4, Entrepreneurship, Federal, Agriculture, Science, Twist, Partnership, Doctor of Philosophy, Genomics, Proteomics, Research, PX, Twist Bioscience, Workflow, Solution, NGS, Senior, Spatial analysis, Risk, Corporate development, Nasdaq, Technology, Medicine, CEO, GLOBE, Fine chemical, Sales

LA JOLLA, Calif., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today announced a partnership with Twist Bioscience to validate its NGS Target Enrichment Solutions, high-quality target enrichment panels either curated or custom, with the G4 sequencing platform.

Key Points: 
  • LA JOLLA, Calif., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today announced a partnership with Twist Bioscience to validate its NGS Target Enrichment Solutions, high-quality target enrichment panels either curated or custom, with the G4 sequencing platform.
  • Twist NGS Target Enrichment Solutions provide an optimized workflow and easy customization of panel content.
  • We are pleased to partner with Twist to make its Target Enrichment Solutions available to Singular Genomics customers.
  • Our partnership with Singular Genomics expands on this commitment to drive innovation in NGS applications, and further expands end-to-end workflow solutions for the NGS community, said Emily M. Leproust, Ph.D., CEO and Co-Founder of Twist Bioscience.

Singular Genomics Partners with Dovetail Genomics to Enable Dovetail Kits for the G4 Sequencing Platform

Retrieved on: 
Montag, Januar 10, 2022
Singular, SEC, OMIC, Dovetail joint, Genome, Gene expression, Chromatin, G4, Federal, Precision medicine, Science, Partnership, Genomics, Proteomics, Solution, PX, Senior, NGS, Spatial analysis, Risk, Corporate development, Nasdaq, Medicine, Developmental biology, GLOBE, Antibiotics

The long-range genomic information captured by Dovetail technology will enable more comprehensive detection of structural variation and chromosome-scale phasing on the Singular Genomics platform.

Key Points: 
  • The long-range genomic information captured by Dovetail technology will enable more comprehensive detection of structural variation and chromosome-scale phasing on the Singular Genomics platform.
  • We are pleased to announce our partnership with Dovetail to make their kits available to Singular Genomics customers.
  • With Dovetails unbiased proximity ligation technology, Singular Genomics users will be able to create a richer view of the genome from every sequencing run, said Dovetail CEO Todd Dickinson.
  • We are thrilled to be partnering with Singular Genomics to enable researchers to accelerate critical advancements in precision medicine and life sciences research.

Singular Genomics Systems, Inc. to Present at the 40th Annual J.P. Morgan Healthcare Conference

Retrieved on: 
Freitag, Januar 7, 2022
Singular, Proteomics, G4, Science, Spatial analysis, Conference, NGS, OMIC, Medicine, Genomics, GLOBE, Nasdaq, Solution, Antibiotics

LA JOLLA, Calif., Jan. 07, 2022 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today announced plans to present virtually at the 40th Annual J.P. Morgan Healthcare Conference.

Key Points: 
  • LA JOLLA, Calif., Jan. 07, 2022 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today announced plans to present virtually at the 40th Annual J.P. Morgan Healthcare Conference.
  • Singular Genomics management is scheduled to present virtually on Wednesday, January 12, 2022at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
  • Singular Genomics is a life science technology company that is leveraging novel, next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians.
  • The G4 and PX Integrated Solutions are both comprised of an instrument and an associated menu of consumable kits.

Singular Genomics Appoints Genomics Research Pioneer Elaine R. Mardis, Ph.D., to Board of Directors

Retrieved on: 
Donnerstag, Januar 6, 2022
Singular, Disease, George Washington University School of Engineering and Applied Science, Supervisory board, Parliamentary Information Technology Committee, University, Pediatrics, Genetic distance, Doctor of Philosophy, Compensation, Director, Chemistry, Science and Technology Select Committee, Hospital, Proteomics, DNA, G4, Cancer, Ohio State University College of Medicine, Federal, Spatial analysis, Risk, Zoology, Institute, NGS, OMIC, Prognosis, Nationwide, PX, Faculty, Health, SEC, Biochemistry, Precision medicine, Medicine, Qiagen, Board, Genomics, GLOBE, Washington University School of Medicine, Technology, Board of directors, Nasdaq, Solution, Industry, Antibiotics, Management, Science

We are thrilled to have Elaine join the Board of Directors.

Key Points: 
  • We are thrilled to have Elaine join the Board of Directors.
  • She brings the rare combination of world-class scientific, industry and governance talents to the role.
  • Singular Genomics is a science and technology company first.
  • Additionally, Dr. Mardis serves on the Supervisory Board, Science and Technology Committee, and the Compensation and Human Resources Committee at Qiagen.

Singular Genomics and Broad Institute Partner to Integrate Advanced Sequencing Technology with the Terra Data Platform

Retrieved on: 
Donnerstag, Januar 6, 2022
Singular, Biomedical Research, Proteomics, G4, Federal, Science, Spatial analysis, Risk, Broad Institute, NGS, OMIC, PX, SEC, Medicine, MIT, Genomics, Verily, GLOBE, Nasdaq, Solution, Harvard University, Microsoft, Antibiotics, Terra

We are thrilled to bring Terras advanced bioinformatic platform to Singular Genomics customers as a plug-and-play bioinformatics solution, said Drew Spaventa, Chairman and Chief Executive Officer of Singular Genomics.

Key Points: 
  • We are thrilled to bring Terras advanced bioinformatic platform to Singular Genomics customers as a plug-and-play bioinformatics solution, said Drew Spaventa, Chairman and Chief Executive Officer of Singular Genomics.
  • With Terra, researchers are more easily and seamlessly able to develop insights from vast amounts of data and advance biomedical research, said Clare Bernard, Senior Director of the Data Sciences Platform at the Broad Institute.
  • We are pleased to facilitate access to Terra as a comprehensive bioinformatic platform for Singular Genomics customers.
  • Terra, developed by the Broad Institute, Microsoft and Verily is a secure, scalable, open-source platform for biomedical researchers to access data, run analysis tools and collaborate.